
OpGen OPGN
Quartalsbericht 2025-Q3
hinzugefügt 19.11.2025
OpGen Kurzfristige Verbindlichkeiten 2011-2026 | OPGN
Kurzfristige Verbindlichkeiten Jährlich OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 634 K | 11.4 M | 10.6 M | 19.9 M | 7.37 M | 4.94 M | 4.38 M | 4.79 M | 5.27 M | 4.89 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 19.9 M | 634 K | 7.42 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
1.71 B | $ 113.78 | 2.96 % | $ 34.6 B | ||
|
Celcuity
CELC
|
44.2 M | $ 140.34 | 7.16 % | $ 6.56 B | ||
|
Co-Diagnostics
CODX
|
3.54 M | $ 2.39 | 21.32 % | $ 3.18 M | ||
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
68.7 M | $ 20.03 | 4.32 % | $ 581 M | ||
|
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
72.9 M | $ 16.41 | 2.88 % | $ 496 M | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
Guardant Health
GH
|
303 M | $ 114.97 | 17.09 % | $ 14.4 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
89.8 M | $ 21.15 | 3.02 % | $ 1.13 B | ||
|
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
4.05 M | - | - | $ 9.42 M | ||
|
ICON Public Limited Company
ICLR
|
2.8 B | $ 115.09 | 1.36 % | $ 9.49 B | ||
|
Interpace Biosciences
IDXG
|
5.1 M | $ 1.8 | - | $ 7.96 M | ||
|
Illumina
ILMN
|
1.55 B | $ 141.92 | 0.17 % | $ 22.6 B | ||
|
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Lantheus Holdings
LNTH
|
333 M | $ 96.09 | 3.44 % | $ 6.49 B | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
Medpace Holdings
MEDP
|
1.34 B | $ 421.87 | 0.47 % | $ 12.2 B | ||
|
Charles River Laboratories International
CRL
|
1.12 B | $ 156.03 | 2.36 % | $ 7.73 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | ||
|
Mettler-Toledo International
MTD
|
1.2 B | $ 1 082.67 | 3.05 % | $ 22.3 B | ||
|
NeoGenomics
NEO
|
88.3 M | $ 8.9 | 6.08 % | $ 1.14 B | ||
|
National Research Corporation
NRC
|
36.6 M | $ 19.26 | 2.72 % | $ 431 M | ||
|
Natera
NTRA
|
310 M | $ 204.92 | 4.53 % | $ 20.2 B | ||
|
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
134 M | $ 3.81 | 7.32 % | $ 353 M | ||
|
Personalis
PSNL
|
39.6 M | $ 7.95 | 12.93 % | $ 709 M | ||
|
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | ||
|
Senseonics Holdings
SENS
|
24.3 M | $ 5.71 | 3.07 % | $ 238 M | ||
|
QIAGEN N.V.
QGEN
|
512 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
61.4 M | - | - | $ 2.69 B | ||
|
Thermo Fisher Scientific
TMO
|
15.2 B | $ 451.79 | 0.9 % | $ 170 B | ||
|
Biomerica
BMRA
|
1.74 M | $ 2.35 | -1.26 % | $ 5.4 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 257.42 | 1.49 % | $ 21.4 B | ||
|
Twist Bioscience Corporation
TWST
|
91.4 M | $ 53.66 | 8.4 % | $ 3.21 B | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
174 M | $ 8.83 | 5.75 % | $ 1.92 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 193.75 | 1.92 % | $ 21.5 B | ||
|
Waters Corporation
WAT
|
1.24 B | $ 341.32 | 2.37 % | $ 20.3 B |